Literature DB >> 30552616

Polymorphisms in XPC gene and risk for prostate cancer.

Rahma Said1,2, Karim Bougatef3, Nouha Setti Boubaker1, Rim Jenni1, Amine Derouiche4, Mohamed Chebil4, Slah Ouerhani5.   

Abstract

Single nucleotide polymorphisms (SNP) in repair gene DNA such as XPC gene can reduce the DNA repair capacity (DRC). Reduced DRC induce genetic instability and may increase the susceptibility to prostate cancer (PC). We conducted a case-controls study to examine the relationship between XPC Lys939Gln and XPC-PAT polymorphisms and the risk for prostate cancer in Tunisian population. We have also correlated molecular results with clinical parameters (Gleason score and TNM status) and lifestyle factors (tobacco status, alcohol consumption, and exposition to professional risk factors) of prostate cancer patients. We have found that the XPC Lys939Gln polymorphism was not associated with a risk of prostate cancer. However the XPC PAT I/I genotype was found to be associated with 3.83-fold increased risk of prostate cancer compared to controls (p = 0.00006; OR 3.83; 95% CI (1.83-8.05)). The test of linkage disequilibrium showed that XPC-PAT polymorphism is in linkage disequilibrium with XPC Lys939Gln variants. The combined analysis of XPC Lys939Gln and XPC-PAT variants showed that patients who inherited (Lys/Gln + PAT D/D) genotypes were protected against prostate cancer development compared to controls. In the other hand, no significant association has been found between XPC polymorphisms and clinical parameters or between XPC polymorphisms and lifestyle factors.

Entities:  

Keywords:  Polymorphism; Prostate cancer; Tunisia; Xeroderma pigmentosum complementary group C

Mesh:

Substances:

Year:  2018        PMID: 30552616     DOI: 10.1007/s11033-018-4572-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  3 in total

Review 1.  Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies.

Authors:  Nawar Al Nasrallah; Benjamin M Wiese; Catherine R Sears
Journal:  Front Oncol       Date:  2022-04-21       Impact factor: 5.738

2.  XPC exon15 Lys939Gln variant increase susceptibility to prostate adenocarcinoma: Evidence based on 4306 patients and 4779 controls.

Authors:  Feng Qin; Sheng-Lin Gao; Kai Xu; Quan-Xin Su; Ze Zhang; Li Shi; Li-Jie Zhu; Li-Feng Zhang; Li Zuo
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

3.  Effects of Xeroderma pigmentosum group C polymorphism on the likelihood of prostate cancer.

Authors:  Yidan Yan; Jianmin Xu; Bin Xu; Qiaxian Wen; Jing Zhou; Lifeng Zhang; Li Zuo; Guoqiang Lv; Yunfeng Shi
Journal:  J Clin Lab Anal       Date:  2020-06-02       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.